In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals, with a price target of $10.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andres Y. Maldonado’s rating is based on Zentalis Pharmaceuticals’ strategic advancements and promising clinical developments. The company is focused on its Cyclin E1+ strategy, particularly with azenosertib, which is being tested in pivotal trials for platinum-resistant ovarian cancer, a condition with significant unmet medical needs. The potential for accelerated approval of azenosertib in this indication represents a near-term value driver for the company.
Moreover, Zentalis is expanding its research into other tumor types by exploring combinations of azenosertib with other therapies, such as T-DXd, in HER2-expressing tumors. This expansion into new solid tumor opportunities demonstrates Zentalis’ commitment to broadening the reach of its therapies. The company’s methodical approach and evidence-based platform reinforce the Buy rating, as these efforts are expected to enhance the therapeutic impact and commercial potential of their lead asset.